Grace Therapeutics, Inc.
GRCE
$4.44
-$0.01-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -146.43% | 72.07% | -628.62% | 115.31% | -21.07% |
| Total Depreciation and Amortization | -- | -100.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.12% | -254.75% | 122.38% | -581.04% | 172.50% |
| Change in Net Operating Assets | 93.18% | -227.66% | 1,266.67% | 90.50% | -444.06% |
| Cash from Operations | 29.05% | -74.51% | 39.03% | 28.21% | 2.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 66.18% | -- | -- |
| Cash from Financing | -- | 100.00% | -102.33% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 157.59% | -47.70% | -119.21% | 370.20% | 3.28% |